FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084584261> ?p ?o ?g. }

• W2084584261 endingPage "115" @default.
• W2084584261 startingPage "110" @default.
• W2084584261 abstract "Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493(palivizumab) is a humanized monoclonal antibody to the fusion protein of RSV and is active in animal models for prevention of pulmonary RSV replication. Objective. To describe the safety, tolerance, immunogenicity and pharmacokinetics of repeat intravenous doses of MEDI-493 in premature infants or infants with bronchopulmonary dysplasia. Design. Phase I/II multicenter, randomized, double blind, placebo-controlled, dose escalation trial. Patient population. Infants born prematurely (≤35 weeks of gestation) who were ≤6 months of age and infants with bronchopulmonary dysplasia who were ≤24 months of age were eligible for study participation. Study agents. Participants received 3, 10 or 15 mg/kg MEDI-493 or 0.9% saline intravenously every 30 days for up to five doses. Results. MEDI-493 was safe and well-tolerated and did not induce a specific anti-MEDI-493 response. The mean half-life of 20 days was comparable with that of other immunoglobulin G preparations. Mean trough serum concentrations 30 days after Infusion 1 were 6.8, 36.1 and 60.6 μg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively. After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 μg/ml. After subsequent doses the mean trough values ranged from 14 to 18 μg/ml in those given 3 mg/kg and were >40 μg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 μg/ml and 88 to 96 μg/ml, respectively). Conclusions. MEDI-493 was safe and well-tolerated in this high risk pediatric population. Mean serum concentrations of MEDI-493 that have been shown to produce a 2-log reduction in pulmonary RSV titer in cotton rats were maintained when 10 or 15 mg/kg MEDI-493 was given every 30 days to pediatric patients at high risk for serious RSV disease. Monthly doses of 15 mg/kg maintained concentrations of >40 μg/ml for the majority of patients." @default.
• W2084584261 created "2016-06-24" @default.
• W2084584261 creator A5001788102 @default.
• W2084584261 creator A5002166091 @default.
• W2084584261 creator A5008163329 @default.
• W2084584261 creator A5017670138 @default.
• W2084584261 creator A5023168748 @default.
• W2084584261 creator A5023331560 @default.
• W2084584261 creator A5026467798 @default.
• W2084584261 creator A5044414310 @default.
• W2084584261 creator A5058606727 @default.
• W2084584261 creator A5072253318 @default.
• W2084584261 creator A5080892509 @default.
• W2084584261 date "1998-02-01" @default.
• W2084584261 modified "2023-10-02" @default.
• W2084584261 title "Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia" @default.
• W2084584261 cites W2019706667 @default.
• W2084584261 cites W2064704406 @default.
• W2084584261 cites W2120325613 @default.
• W2084584261 cites W2133963352 @default.
• W2084584261 cites W2265593905 @default.
• W2084584261 cites W2316897460 @default.
• W2084584261 cites W2328116798 @default.
• W2084584261 cites W4245170709 @default.
• W2084584261 doi "https://doi.org/10.1097/00006454-199802000-00006" @default.
• W2084584261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9493805" @default.
• W2084584261 hasPublicationYear "1998" @default.
• W2084584261 type Work @default.
• W2084584261 sameAs 2084584261 @default.
• W2084584261 citedByCount "196" @default.
• W2084584261 countsByYear W20845842612012 @default.
• W2084584261 countsByYear W20845842612013 @default.
• W2084584261 countsByYear W20845842612014 @default.
• W2084584261 countsByYear W20845842612015 @default.
• W2084584261 countsByYear W20845842612016 @default.
• W2084584261 countsByYear W20845842612017 @default.
• W2084584261 countsByYear W20845842612018 @default.
• W2084584261 countsByYear W20845842612019 @default.
• W2084584261 countsByYear W20845842612020 @default.
• W2084584261 countsByYear W20845842612021 @default.
• W2084584261 countsByYear W20845842612022 @default.
• W2084584261 countsByYear W20845842612023 @default.
• W2084584261 crossrefType "journal-article" @default.
• W2084584261 hasAuthorship W2084584261A5001788102 @default.
• W2084584261 hasAuthorship W2084584261A5002166091 @default.
• W2084584261 hasAuthorship W2084584261A5008163329 @default.
• W2084584261 hasAuthorship W2084584261A5017670138 @default.
• W2084584261 hasAuthorship W2084584261A5023168748 @default.
• W2084584261 hasAuthorship W2084584261A5023331560 @default.
• W2084584261 hasAuthorship W2084584261A5026467798 @default.
• W2084584261 hasAuthorship W2084584261A5044414310 @default.
• W2084584261 hasAuthorship W2084584261A5058606727 @default.
• W2084584261 hasAuthorship W2084584261A5072253318 @default.
• W2084584261 hasAuthorship W2084584261A5080892509 @default.
• W2084584261 hasConcept C112705442 @default.
• W2084584261 hasConcept C126322002 @default.
• W2084584261 hasConcept C142724271 @default.
• W2084584261 hasConcept C204787440 @default.
• W2084584261 hasConcept C27081682 @default.
• W2084584261 hasConcept C2778376644 @default.
• W2084584261 hasConcept C2778644256 @default.
• W2084584261 hasConcept C2778721537 @default.
• W2084584261 hasConcept C2779234561 @default.
• W2084584261 hasConcept C2908647359 @default.
• W2084584261 hasConcept C534529494 @default.
• W2084584261 hasConcept C54355233 @default.
• W2084584261 hasConcept C71924100 @default.
• W2084584261 hasConcept C86803240 @default.
• W2084584261 hasConcept C90924648 @default.
• W2084584261 hasConcept C99454951 @default.
• W2084584261 hasConceptScore W2084584261C112705442 @default.
• W2084584261 hasConceptScore W2084584261C126322002 @default.
• W2084584261 hasConceptScore W2084584261C142724271 @default.
• W2084584261 hasConceptScore W2084584261C204787440 @default.
• W2084584261 hasConceptScore W2084584261C27081682 @default.
• W2084584261 hasConceptScore W2084584261C2778376644 @default.
• W2084584261 hasConceptScore W2084584261C2778644256 @default.
• W2084584261 hasConceptScore W2084584261C2778721537 @default.
• W2084584261 hasConceptScore W2084584261C2779234561 @default.
• W2084584261 hasConceptScore W2084584261C2908647359 @default.
• W2084584261 hasConceptScore W2084584261C534529494 @default.
• W2084584261 hasConceptScore W2084584261C54355233 @default.
• W2084584261 hasConceptScore W2084584261C71924100 @default.
• W2084584261 hasConceptScore W2084584261C86803240 @default.
• W2084584261 hasConceptScore W2084584261C90924648 @default.
• W2084584261 hasConceptScore W2084584261C99454951 @default.
• W2084584261 hasIssue "2" @default.
• W2084584261 hasLocation W20845842611 @default.
• W2084584261 hasLocation W20845842612 @default.
• W2084584261 hasOpenAccess W2084584261 @default.
• W2084584261 hasPrimaryLocation W20845842611 @default.
• W2084584261 hasRelatedWork W1589200039 @default.
• W2084584261 hasRelatedWork W187419195 @default.
• W2084584261 hasRelatedWork W2001093521 @default.
• W2084584261 hasRelatedWork W2002642430 @default.
• W2084584261 hasRelatedWork W2223258418 @default.
• W2084584261 hasRelatedWork W2406407808 @default.
• W2084584261 hasRelatedWork W2412634366 @default.

• next